Skip to main navigation Skip to search Skip to main content

Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study

  • et al.

Research output: Contribution to journal › Article (Academic Journal) › peer-review

96 Citations (Scopus)
603 Downloads (Pure)

Abstract

ABSTRACT
Background: Limited empirical evidence exists for hepatitis C virus (HCV) treatment-as-prevention. The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study assessed HCV treatment-as-prevention in four Australian prisons.
Methods: SToP-C is a non-randomised trial, including a pre/post analysis within a prospective longitudinal cohort of people incarcerated in two maximum- (male) and two medium-security prisons (one male, one female). All prison inmates at least 18 years were eligible for enrolment. Participants were enrolled from late-2014 to 2019. Following HCV testing, participants were monitored for risk behaviors and HCV, among three sub-populations: 1) uninfected (HCV antibody negative); 2) previously infected (HCV antibody positive, HCV RNA negative); 3) infected (HCV antibody and HCV RNA positive). Uninfected and previously infected (at-risk) participants were followed every 3-6 months for HCV primary infection and re-infection, respectively. Infected participants were assessed for treatment, initially standard of care treatment (by prison health services), followed by direct-acting antiviral (DAA) treatment scale-up from mid-2017 (12 weeks sofosbuvir/velpatasvir, through SToP-C). Participants were followed until study closure in November 2019. The primary study outcome was HCV incidence compared between pre- and post-treatment scale-up periods among participants at risk of HCV primary infection or re-infection. The trial was registered with ClinicalTrials.gov (identifier: NCT02064049)
Findings: Of 3,691 participants enrolled, 719 (19%) had detectable HCV RNA and 2,965 were at-risk of primary infection (n=2,240) or re-infection (n=725) at baseline. DAA treatment was initiated in 349/499 eligible participants during the treatment scale-up period. Among at-risk population with longitudinal follow-up (n=1,643; median age 33 years; 82% male), 31% reported injecting drug use in prison. HCV incidence declined by 48%, from 8.31 to 4.35/100 person-years between pre- and post-treatment scale-up periods [Incidence Rate Ratio (IRR): 0.52, 95%CI: 0.36, 0.78]. Incidence of primary infection declined from 6.64 to 2.85/100 person-years (IRR: 0.43, 95%CI: 0.25, 0.74), while incidence of re-infection declined from 12.36 to 7.27/100 person-years (IRR: 0.59, 95%CI: 0.35, 1.00). Among participants reporting injecting drug use in the current imprisonment, incidence of primary infection declined from 39.08 to 14.03/100 person-years (IRR: 0.36, 95%CI: 0.16, 0.80), and incidence of re-infection declined from 15.26 to 9.34/100 person-years (IRR: 0.61, 95%CI: 0.34, 1.09). Adjusted analysis indicated a significant reduction in HCV risk between pre- and post-treatment scale-up periods (adjusted Hazard Ratio: 0.50, 95% CI: 0.33, 0.76).
Interpretation: DAA treatment scale-up was associated with reduced HCV incidence in prison, indicative of HCV treatment-as-prevention. The findings support broad DAA treatment scale-up among incarcerated populations.

Original languageEnglish
Pages (from-to)533-546
Number of pages14
JournalThe Lancet Gastroenterology and Hepatology
Volume6
Issue number7
Early online date6 May 2021
DOIs
Publication statusPublished - 1 Jul 2021

Bibliographical note

Funding Information:
Research reported in this Article was supported by an Australian National Health and Medical Research Council (NHMRC) Partnership Project Grant (APP1092547), and Gilead Sciences. The Kirby Institute is funded by the Australian Government's Department of Health and Ageing. The SToP-C study was a partnership project involving the Kirby Institute, Justice Health and Forensic Mental Health Network, Corrective Services NSW, NSW Ministry of Health, NSW Users and AIDS Association, Hepatitis NSW, and Gilead Sciences. The SToP-C study group included members of the protocol steering committee; coordinating centre, The Kirby Institute, UNSW Sydney; and study site co-ordinators. The views expressed in this Article are those of the authors and do not necessarily represent the position of the Australian Government or Gilead Sciences. ARL and GJD were supported by NHMRC Practitioner Fellowships. JG was supported by an NHMRC Investigator Grant. TB was supported by an NHMRC Fellowship. EBC is supported by a postdoctoral fellowship from the Canadian Network on Hepatitis C. PV acknowledges support from the US National Institute for Drug Abuse (NIDA grant numbers R01 AI147490, R01 DA033679, R01 DA037773, R21 DA046809, and R01 DA047952), the National Institute for Health Research Health Protection Research Unit (NIHR HPRUs) in Evaluation of Interventions and Behavioural Science at the University of Bristol, and the NIHR funded EPIToPe project. NKM acknowledges support from the US National Institute of Allergy and Infectious Diseases (NIAID) and NIDA (R01 AI147490), and the UCSD Center for AIDS Research, a programme funded by the US National Institutes of Health (P30 AI036214).

Funding Information:
This study was funded jointly by the Australian National Health and Medical Research Council (NHMRC) and Gilead Sciences through a NMHRC Partnership Project grant. Gilead Sciences provided the study medication. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The sponsor (The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia) collected the data, managed study samples, and monitored study conduct.

Funding Information:
Research reported in this Article was supported by an Australian National Health and Medical Research Council (NHMRC) Partnership Project Grant ( APP1092547 ), and Gilead Sciences. The Kirby Institute is funded by the Australian Government's Department of Health and Ageing. The SToP-C study was a partnership project involving the Kirby Institute, Justice Health and Forensic Mental Health Network, Corrective Services NSW, NSW Ministry of Health, NSW Users and AIDS Association, Hepatitis NSW, and Gilead Sciences. The SToP-C study group included members of the protocol steering committee; coordinating centre, The Kirby Institute, UNSW Sydney; and study site co-ordinators. The views expressed in this Article are those of the authors and do not necessarily represent the position of the Australian Government or Gilead Sciences. ARL and GJD were supported by NHMRC Practitioner Fellowships. JG was supported by an NHMRC Investigator Grant. TB was supported by an NHMRC Fellowship. EBC is supported by a postdoctoral fellowship from the Canadian Network on Hepatitis C. PV acknowledges support from the US National Institute for Drug Abuse (NIDA grant numbers R01 AI147490, R01 DA033679, R01 DA037773, R21 DA046809, and R01 DA047952), the National Institute for Health Research Health Protection Research Unit (NIHR HPRUs) in Evaluation of Interventions and Behavioural Science at the University of Bristol, and the NIHR funded EPIToPe project. NKM acknowledges support from the US National Institute of Allergy and Infectious Diseases (NIAID) and NIDA (R01 AI147490), and the UCSD Center for AIDS Research, a programme funded by the US National Institutes of Health (P30 AI036214).

Funding Information:
GJD is a consultant and adviser for, and has received research grants from, Gilead, AbbVie, Merck, Bristol-Myers Squibb, and Cepheid. ARL is a consultant and adviser for, and has received investigator-initiated research grants from, Gilead, Merck, and Bristol-Myers Squibb. JG is a consultant and adviser for, and has received research grants from, Gilead, AbbVie, Merck, and Cepheid. PV has received investigator-initiated untied grants from Gilead and honorarium from Gilead and Merck. NKM has received unrestricted research grants from Gilead and Merck. JGMc is a stockholder and ex-employee of Gilead Sciences. DMB is a stockholder and employee of Gilead Sciences. All other authors declare no competing interests.

Publisher Copyright:
© 2021 Elsevier Ltd

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Groups and Themes

  • GEM-B

Fingerprint

Dive into the research topics of 'Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study'. Together they form a unique fingerprint.

Cite this